Notícias

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on year to $481 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.

Halozyme earnings beat and guidance hike reshape the story Halozyme Therapeutics (HALO) just put fresh numbers on the table, reporting second quarter 2026 results, raising full year revenue guidance and updating progress on its share repurchase programs. For the quarter ended June 30, 2026, revenue was reported at US$481 million compared with US$325.72 million for the same period a year earlier. Net income for the quarter was US$229.91 million compared with US$165.16 million a year ago. Basic...

Halozyme's ENHANZE platform drives a 48% revenue surge, with new partnerships and Hypercon progress fueling a second growth engine.

Moby summary of Halozyme Therapeutics, Inc.'s Q2 2026 earnings call

Halozyme Therapeutics (NASDAQ:HALO) reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from newer product launches and revenue from newly signed collaboration agreements. Total revenue rose

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.28% and +17.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 47.7% year on year to $481 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the expanding adoption of subcutaneous drug delivery through its ENHANZE technology. CEO Helen Torley credited the quarter’s momentum to broader use of key partner products such as DARZALEX, VYVGART Hytrulo, and PHESGO, with royalty streams up 43% year-over-year. The company also benefited from ramping contributions from recently launched therapies

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Monday after market close. Here’s what to expect.

Halozyme Therapeutics Inc (HALO) reports a 42% revenue surge, unveils a $1 billion share buyback, and outlines ambitious growth plans for 2026.

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization. On the company’s earnings call, President and CEO

While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ANI (ANIP) delivered earnings and revenue surprises of +60.16% and +15.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Besides Wall Street's top-and-bottom-line estimates for Halozyme Therapeutics (HALO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.

Halozyme Therapeutics (NASDAQ:HALO) stockholders elected two Class I directors and approved several governance items at the company’s annual meeting, while President and CEO Helen Torley highlighted 2025 execution, recent acquisitions, new commercial agreements, and updated financial guidance. Stoc

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.